We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Sonya
Abraham
s.abraham@imperial.ac.uk
Prof
Julien
Marchesi
j.marchesi@imperial.ac.uk
Inflammatory polyarthropathiesSpondylopathiesPapulosquamous disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Psoriatic Arthritis is a joint problem (arthritis) that often occurs with a skin condition called psoriasis. Psoriasis is a common skin problem that causes red scaly patches on the body, and it is an on-going (chronic) inflammatory condition. Around 30 percent of those with psoriasis will develop arthritis with the skin condition. In most cases, psoriasis comes before the arthritis. Therefore the presence of skin psoriasis is a major risk factor for the development of an inflammatory form of arthritis. Additional risk factors included obesity, smoking, the presence of nail psoriasis and possibly the severity and distribution of psoriasis, all factors that may be linked to the host’s microbiome.
Ankylosing Spondylitis is a long-term type of arthritis that mainly affects the joints of the spine (back). It causes inflammation that leads to pain, stiffness with limited back mobility and tiredness. It affects 200,000 people in the United Kingdom and one female for every three males. Although linked to a particular gene found in up to 9 out of 10 patients with ankylosing spondylitis, the cause is also still unknown.
The purpose of this study is to identify, group into classes and mark the differences in gut microorganisms (microbiome) found in patients with psoriatic arthritis and ankylosing spondylitis, and compared to participants without these conditions and consider themselves "health".
We are looking to recruit 200 participants in total to this study. This includes 100 people with psoriatic arthritis, 50 people with Ankylosing spondylitis and 50 people without both conditions.
Eligible participants at screening visit will be allocated into Group A (50 PsA) to attend four visits at screening, week-0, week-12 and week-24 respectively. Group B (50 PsA), Group C (50 AS), Group D (HC) to attend screening and week- 0 (baseline) only.
Schedule of events will involve data collection of medical and medication history, demographics, physical examination, diet and lifestyle questionnaires, food diary, vital signs (BP,pulse and) weight, height (BMI), examination of patient joints and skin, disease activity scores, patient reported outcomes by health and quality of life questionnaires. Routine blood tests, study specific blood, DNA assessment, urine and stool sample collection.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
EXCLUSION CRITERIA Participants who meet any of the following criteria will be excluded from the study entry: General medical 1. Breastfeeding. 2. Gastroenteritis (diarrhoea and vomiting) four weeks prior enrolment. 3. Gastrointestinal symptoms such as recurrent abdominal pain or discomfort, chronic diarrhoea and constipation. 4. Known or suspected primary or secondary immunodeficiency/ immunosuppression. 5. Endoscopy or colonoscopy procedures 8 weeks prior enrolment. 6. Diagnosed with cancer within the past 3 years. 7. Gastro-Intestinal surgery in the last 6 months. Drug – specific 8. Treated with oral steroids or corticosteroids three months prior enrolment. 9. Systemic antibiotics three months prior enrolment. 10. Regular or recent (within 4 weeks) use of proton pump inhibitors (PPI) (Omeprazole, Lansoprazole, Pantoprazole, Esomeprazole, Rabeprazole, Ilaprazole) 11. Regular or recent use of H2 antagonists (cimetidine, famotidine, nizatidine and ranitidine), 12. History of alcohol, drugs or chemical abuse within 3 months prior to screening. 13. Regular use of laxatives and, or recent use of agents that affect gut motility.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by VERSUS ARTHRITIS .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34590
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
